A prospective, randomized study assessing different modalities for flushing totally implanted vascular access device in children with malignancy
Authors:
Open Access
- 6 August 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 85 (1) , 114-119
Abstract
Background: The totally implanted vascular access device (TIVAD) is commonly used in patients with malignant tumors requiring chemotherapy or long-term intravenous infusion and those with difficulty placing peripheral venous catheters. It could also be used to draw blood in pediatric patients. Thus, how to maintain the patency and longevity of TIVAD is always emphasized. Methods: In this prospective study, TIVAD was randomly infused in patients under 18 years with three different concentrations of heparinized solutions: 10 mL with 100 U/mL heparin, 20 mL with 10 U/mL heparin, and 30 mL with 10 U/mL heparin. Results: A total of 81 patients (46 males and 35 females) were enrolled in this study from August 2, 2013 to February 1, 2017. The mean age of those who received TIVAD implantation was 7.2 ± 5.3 years, and the mean duration of using TIVAD was 1027.6 ± 369.1 days. Patients without catheter occlusion events experienced significantly shorter hospitalizations, fewer admissions, and fewer punctures than those with catheter occlusion events (p < 0.05). The administration and frequency of blood transfusions, history of bacteremia, and medication history did not increase the risk of catheter occlusion, but puncture frequency increased this risk. In patients with catheter occlusion events (38/81, 46.9%), catheter patency was restored after instillation of urokinase solution. Conclusion: In this study, the risk of TIVAD catheter occlusion was only related to puncture frequency regardless of the heparin flush composition or patient characteristics. A high puncture frequency of TIVAD during the 3.5-year study period significantly increased the risk of catheter occlusion. Besides, flushing and locking solutions for TIVAD using heparin at 10 U/mL was effective as using heparin at 100 U/mL regardless of the flushing volume of 10, 20, or 30 mL.Keywords
This publication has 23 references indexed in Scilit:
- Thrombosis and acute leukemiaHematology, 2012
- A Multidisciplinary Approach to Determine Heparin Dosing in Pediatric Vascular DevicesJournal of Pediatric Oncology Nursing, 2010
- Prospective, Randomized Trial of Two Different Modalities of Flushing Central Venous Catheters in Pediatric Patients With CancerJournal of Clinical Oncology, 2009
- Restoring Patency to Central Venous Access DevicesClinical Journal of Oncology Nursing, 2008
- Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patientsAmerican Journal of Infection Control, 2008
- INFECTIONS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: An Analysis of 222 Febrile Neutropenic EpisodesPediatric Hematology and Oncology, 2008
- Thrombosis and acute lymphoblastic leukaemiaBritish Journal of Haematology, 2007
- Phase II Trial of Alfimeprase, a Novel-Acting Fibrin Degradation Agent, for Occluded Central Venous Access DevicesJournal of Clinical Oncology, 2006
- Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devicesAnnals of Oncology, 2005
- Evaluation of thrombotic children with malignancyAnnals of Hematology, 2005